Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective-Reference-Cited by-同舟云学术

Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective

Published:2023-09-09 Issue:1 Volume:26 Page:1108-1121
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Dhanji Nishit¹,Decimoni Tassia Cristina²^ORCID,Dyer Matthew T. D.³,May Jessica R.³^ORCID,van de Wetering Gijs⁴,Petersohn Svenja⁴^ORCID,Nickel Katharina⁵,Silva Amanda⁶,Muniz David Q. B.⁷,Casagrande D. Oliveira Ana Paula²

Affiliation:

1. Modeling & Meta-Analysis, OPEN Health, Oxford, UK

2. Health Economics and Outcomes Research, Bristol Myers Squibb, São Paulo, SP, Brazil

3. WW Health Economics and Outcomes Research, Bristol Myers Squibb, Uxbridge, UK

4. Modeling & Meta-Analysis, OPEN Health, Rotterdam, Netherlands

5. Modeling & Meta-Analysis, OPEN Health, Berlin, Germany

6. Commercialization Intercon Medical, Medical and Regulatory Affairs, São Paulo, SP, Brazil

7. Hospital Sírio-Libanês, São Paulo, Brazil

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2252716

Reference48 articles.

1. International Agency for Research on Cancer (IARC). Brazil fact sheets. GLOBOCAN 2020. Available from: https://gco.iarc.fr/today/data/factsheets/populations/76-brazil-fact-sheets.pdf.

2. An estimate of premature deaths averted with immunotherapy in treating Brazilian patients with advanced clear cell renal cell carcinoma. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e16114#:∼:text=Background%3A%20Clear%20cell%20renal%20cell in%20metastatic%20RCC%20(mRCC).

3. Brazilian data of renal cell carcinoma in a public university hospital

4. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective

5. Immunotherapy-based first-line treatment of intermediate- and poor-risk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma;Oncology and Therapy;2024-08-10